GC Genome, a company specializing in genomic analysis, has officially entered the Middle Eastern market by signing a supply agreement for 'GeniFit,' its non-invasive prenatal test (NIPT), with Volbert Medical LLC, a distributor specializing in medical devices and healthcare solutions based in the United Arab Emirates (UAE). This agreement is expected to be a significant stepping stone for GC Genome's expansion into the global market.

 
'GeniFit,' an Accumulation of Proprietary Technology, Protects Maternal and Fetal Health with High Accuracy

GC Genome's 'GeniFit' is a non-invasive prenatal test that extracts fetal DNA from the mother's blood to check for chromosomal abnormalities. Notably, it utilizes next-generation sequencing (NGS) techniques, incorporating GC Genome's proprietary technology, boasting higher accuracy and reliability than existing testing methods.

The core competitive edge of GeniFit lies in its world-first adoption of artificial intelligence (AI) technology and the DNA fragment length (FD) concept. This innovative technological integration significantly enhances the sensitivity and specificity of the test, allowing for accurate detection of major trisomies like Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13), as well as sex chromosome aneuploidies and microdeletion/duplication syndromes. This offers a significant advantage by reducing the risks of unnecessary invasive procedures (such as amniocentesis or chorionic villus sampling) for mothers while enabling early detection of the fetus's genetic health.

 
UAE Non-Invasive Prenatal Testing Market Growing at Over 19% Annually; Successful Settlement Expected for GC Genome

Through this supply agreement, GC Genome plans to enhance its brand recognition and expand its market share in the UAE in the mid to long term. The UAE is a very attractive market for GC Genome, with a steady increase in demand for early diagnosis of genetic disorders before birth, and the non-invasive prenatal testing market, in particular, showing high growth of over 19% annually. The growing preference for safe and accurate prenatal tests due to increasing maternal age and greater awareness of genetic disorders is driving this market growth.

Volbert Medical LLC, the partner company, has established an extensive network of hospitals and clinics within the UAE based on its long-standing experience and expertise in medical equipment and hospital systems. Furthermore, it possesses strong distribution channels in key Middle Eastern countries such as Saudi Arabia, Qatar, Oman, Kuwait, and Bahrain, suggesting a high possibility for GC Genome's 'GeniFit' service to expand across the entire Middle East in the future. This signifies that GC Genome has laid a strong foundation for long-term growth in the Middle Eastern market.

 
Expanding Service Portfolio with Rare Genetic Disease Testing; Accelerating Global Market Penetration

Ki-chang Suk, CEO of GC Genome, stated, "Through this collaboration with Volbert Medical LLC, GC Genome plans to establish a foundation for expanding its service portfolio to include rare genetic disease testing." This demonstrates GC Genome's strategy to move beyond simply supplying NIPT and to address various genomic testing demands in the Middle East, with the UAE as its base.

GC Genome has already gained recognition for its excellent genomic analysis technology and product quality both domestically and internationally. This entry into the UAE market signifies its determination to accelerate its penetration into overseas markets based on this competitiveness. The Middle East is considered a region with significant growth potential in the genomic testing market due to high birth rates and active government investment in expanding medical infrastructure. Starting with 'GeniFit,' GC Genome is expected to introduce various genomic analysis services to the Middle Eastern market, further solidifying its position as a global genomic analysis company.

 
Future Prospects and Implications

GC Genome's entry into the UAE market is noteworthy as a successful case of a Korean bio-healthcare company expanding overseas. Especially for non-invasive prenatal testing, which is crucial for early detection of maternal and fetal health, technology and reliability are paramount. GC Genome's proprietary AI and DNA fragment length analysis technology is expected to meet these demands and secure a competitive edge in the Middle Eastern market.

All eyes are now on how GC Genome, through its collaboration with Volbert Medical LLC, will create new opportunities in the Middle East and lead the genomic analysis market.

[Copyright (c) Global Economic Times. All Rights Reserved.]